<DOC>
	<DOCNO>NCT02868229</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled trial design evaluate safety , pharmacokinetics , pharmacodynamic effect multiple dos COR-001 placebo</brief_summary>
	<brief_title>Study Assess Safety , Pharmacokinetics , Pharmacodynamics Multiple Doses COR-001</brief_title>
	<detailed_description />
	<criteria>INCLUSION CRITERIA 1 . Age 18 80 year 2 . The patient agree comply contraception reproduction restriction study 3 . Receiving intravenous ( IV ) subcutaneous ( SC ) erythropoietin stimulate agent ( ESA ) drug continuously prescribe minimum 8 week prior Screening 4 . At least 2 ferritin value Screening &gt; 300 ng/mL 5 . At least 2 transferrin saturation ( TSAT ) value Screening 15 % 50 % ( inclusive ) EXCLUSION CRITERIA : 1 . Use systemic immunosuppressive drug Screening Period anticipate use drug time study 2 . Clinical evidence suspicion active smolder infection clinical serologic criterion 3 . Actively treat active malignancy 4 . Known suspected occult active bleeding 5 . Received red blood cell whole blood transfusion within 2 month prior Screening anticipate receive blood transfusion time study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>